Clinical significance of CD34
10.1007/s11684-021-0836-7
- Author:
Xueping LI
1
;
Yuting DAI
1
;
Bing CHEN
1
;
Jinyan HUANG
1
;
Saijuan CHEN
1
;
Lu JIANG
2
Author Information
1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jianglu125@126.com.
- Publication Type:Journal Article
- Keywords:
CD34+CD117dim/CD34+CD117bri cell population;
gene expression;
prognosis;
t(8;
21)(q22;
q22) AML
- MeSH:
Gene Expression;
Granulocyte Precursor Cells;
Humans;
Immunophenotyping;
Leukemia, Myeloid, Acute/genetics*;
Membrane Glycoproteins;
Prognosis;
Proteins;
Proto-Oncogene Proteins c-kit/genetics*
- From:
Frontiers of Medicine
2021;15(4):608-620
- CountryChina
- Language:English
-
Abstract:
t(8;21)(q22;q22) acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy with a high relapse rate in China. Two leukemic myeloblast populations (CD34
